HLA class II-presented tumor-associated antigen epitopes (HLA-II TAA epitopes)

HLA class II-presented tumor-associated antigen (TAA) epitopes are peptide fragments derived from tumor-specific or overexpressed proteins that are displayed on the cell surface by Human Leukocyte Antigen (HLA) class II molecules, such as HLA-DR, HLA-DQ, and HLA-DP (PubMed: 31110334). While HLA class I molecules present antigens to CD8+ cytotoxic T cells, HLA class II molecules primarily present to CD4+ helper T cells, which are essential for orchestrating a comprehensive anti-tumor immune response (Nature: 10.1038/s41586-019-1524-z). These epitopes play a critical role in cancer immunology by facilitating the recruitment of B cells and the activation of CD8+ T cells through cytokine signaling, such as IL-2 and IFN-gamma (Frontiers in Immunology: 10.3389/fimmu.2019.01062). In the context of disease, many tumors downregulate HLA class II to evade immune detection, making the restoration or targeting of these complexes a key therapeutic strategy. Therapeutic interventions targeting these epitopes include peptide-based vaccines like SurVaxM and personalized neoantigen vaccines, which aim to stimulate long-lasting T-cell memory and direct anti-tumor activity (JCI: 10.1172/JCI125560). Additionally, TCR-engineered T-cell therapies are being developed to specifically recognize these MHC-II/peptide complexes to treat various malignancies (Science: 10.1126/science.aak9517).

Other names

MHC class II-restricted tumor antigensHLA-II tumor antigensCD4+ T cell tumor epitopesTumor-associated antigen-derived MHC-II peptidesMHC-II/peptide complexes

Induction of antigen-specific CD4+ T-cell responses to enhance anti-tumor immunity and provide help for CD8+ T-cell activation.